Ken Newman

Ken Newman is the current Vice President of Clinical Development at Ionis Pharmaceuticals. Prior to this, they served as Chief Medical Officer at Verona Pharma from January 2015 to April 2018. From December 2013 to December 2014, they were Head of Global Clinical Development and Chief Development Officer at Mesoblast. From January 2010 to November 2013, they were Executive Vice President and Chief Medical Officer at Acton Pharmaceuticals, Inc. From January 2006 to December 2010, they were Vice President of Medical Affairs at Boehringer Ingelheim. From January 1997 to December 2006, they were Executive Director at Forest Laboratories, Inc., responsible for clinical development and medical affairs for numerous therapeutic categories.

Ken Newman graduated from Duke University with a B.S. in Biophysics. Ken then attended UTHealth Houston for their M.D. After completing their Internal Medicine Residency at Duke University School of Medicine, they completed their Pulmonary Critical Care Fellowship at The Johns Hopkins University School of Medicine. Ken Newman then went on to earn their MBA in Management from the University of Cincinnati Carl H. Lindner College of Business.

Their manager is Eugene Schneider, Executive Vice President, Chief Clinical Development Officer. Some of their coworkers include Michael McCaleb - VP, Clinical Development, Roger Lane - VP, Clinical Development.